AZ signs up Foundation Medicine for Lynparza diagnostic
AstraZeneca has signed up Foundation Medicine to develop a novel companion diagnostic assay for its cancer drug Lynparza that will enable doctors to identify patients most likely to benefit from it.
Read More
